BioCentury | Dec 3, 2012
Clinical News

K-Ras and BRAF mutation screening diagnostic data

...Darmstadt, Germany) markets Erbitux elsewhere, except in Japan where the 3 companies market the drug. HealthPartners Research Foundation...
BioCentury | Nov 29, 2012
Clinical News

Researchers question benefits of K-Ras screening

...Researchers at the HealthPartners Research Foundation said screening for K-Ras (KRAS) mutations prior to starting treatment with Erbitux...
BioCentury | Mar 9, 2009
Company News

Sanomune, HealthPartners Research Foundation deal

...targeting amyloid-beta and tau protein. Financial terms were not disclosed. Sanomune Inc. , Winnipeg, Manitoba HealthPartners Research Foundation...
Items per page:
1 - 3 of 3
BioCentury | Dec 3, 2012
Clinical News

K-Ras and BRAF mutation screening diagnostic data

...Darmstadt, Germany) markets Erbitux elsewhere, except in Japan where the 3 companies market the drug. HealthPartners Research Foundation...
BioCentury | Nov 29, 2012
Clinical News

Researchers question benefits of K-Ras screening

...Researchers at the HealthPartners Research Foundation said screening for K-Ras (KRAS) mutations prior to starting treatment with Erbitux...
BioCentury | Mar 9, 2009
Company News

Sanomune, HealthPartners Research Foundation deal

...targeting amyloid-beta and tau protein. Financial terms were not disclosed. Sanomune Inc. , Winnipeg, Manitoba HealthPartners Research Foundation...
Items per page:
1 - 3 of 3